Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer

Zhao, Kunpeng; Cheng, Jing; Chen, Baojun; Liu, Qi; Xu, Di; Zhang, Yongjian

doi:10.21037/jtd.2017.09.01

Cited by 48 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These analyses demonstrated that the potential underlying molecular mechanisms of AC124804.1 function were pathways involving proteasome, peroxisome and SNARE interactions in vesicular transport, which have confirmed roles in tumorigenesis and progression in previous studies (37)(38)(39). MIR34AHG is the host gene of miR-34a and consequently may have biological functions associated with the miR-34 family, which may have suppressive functions in LUAD as previously demonstrated (40,41). The relationship between these two lncRNAs and LUAD should be studied further.…”

Section: Discussionsupporting

confidence: 78%

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Zhang

2020

Oncol Lett

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have a number of functions in various cellular processes and are potential prognostic factors for lung adenocarcinoma (LUAD). A gene risk model could provide novel evidence to improve the prediction of overall outcomes and provide more potential biomarkers. The present study aimed improve a previously published method of gene signature construction to make it more robust and accurate. The lncRNA expression profiles from 594 patients with LUAD were obtained from The Cancer Genome Atlas (TCGA) database and samples were divided into high-and low-risk groups based on median risk scores calculated using a prognosis-related risk score formula. Univariate Cox regression, least absolute shrinkage and selection operator algorithm and multivariate Cox regression were performed to construct a gene signature based on the differentially expressed lncRNAs in patients with LUAD. The robustness and accuracy of the present model was assessed using area under the calculated curves (AUC) and Kaplan-Meier (K-M) survival analysis of the high-and low-risk cohorts. Potential biomarkers associated with survival status were then identified using K-M survival analysis and potential biomarker functions were predicted using enrichment analysis of co-expressed mRNAs. The gene signature constructed contained 44 lncRNAs. The AUCs for 3-and 5-year survival with the model were 0.836 and 0.818, respectively, of a time-dependent receiver operator characteristic curve. Moreover, lncRNAs AC124804.1 and MIR34AHG were identified using K-M survival analysis and the potential function of these two lncRNAs was predicted using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment. The present lncRNA model provides novel insight which may improve prediction of prognosis for patients with LUAD and identify potentially novel biomarkers for the diagnosis.

show abstract

Section: Discussionsupporting

confidence: 78%

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Zhang

2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…This is evident from several published reports that have shown the use of circulating miRNAs in early cancer detection, such as miR‐196a in gastric cancer, and the diagnostic roles of miR‐106b‐3p, miR‐101‐3p, and miR‐1246 in hepatocellular carcinoma . In lung cancer, low expression of the circulating miRNA‐34 family was associated with clinicopathological status and poor progression‐free and overall survival of NSCLC patients . miR‐223, miR‐20a, miR‐448, and miR‐145, as serum/plasma miRNA signatures, have shown high sensitivity (>80%), whereas another panel including miR‐628‐3p, miR‐29c, miR‐210, and miR‐1244 have shown high specificity (>90%) to stage I‐II NSCLC samples .…”

Section: Introductionmentioning

confidence: 99%

“…17 In lung cancer, low expression of the circulating miRNA-34 family was associated with clinicopathological status and poor progression-free and overall survival of NSCLC patients. 18 miR-223, miR-20a, miR-448, and miR-145, as serum/plasma miRNA signatures, have shown high sensitivity (>80%), whereas another panel including miR-628-3p, miR-29c, miR-210, and miR-1244 have shown high specificity (>90%) to stage I-II NSCLC samples. 19 Although several circulating miRNAs have been found to be associated with NSCLC, to date, their functional relevance in NSCLC has not been well characterized.…”

mentioning

confidence: 99%

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Despite the availability of various diagnostic procedures, a tissue biopsy is still indispensable for the routine diagnosis of lung cancer. However, inaccurate diagnoses can occur, leading to inefficient cancer management. In this context, use of circulating microRNAs (miRNAs) may serve as diagnostic tools as liquid biopsies, and as biomarkers to better understand the molecular mechanisms involved in the progression of cancer. We identified miR‐590‐5p as a potential prognostic marker in the progression of non‐small cell lung cancer (NSCLC). We were able to detect this miRNA in blood plasma samples of NSCLC patients through quantitative real‐time PCR. Our data showed an ~7.5‐fold downregulation of miR‐590‐5p in NSCLC patients compared to healthy controls, which correlated with several clinicopathological features. Further, overexpression of miR‐590‐5p led to decreased cell viability, proliferation, colony formation, migration, and invasion potential of lung cancer cells, whereas its knockdown showed the opposite effect. In addition, the levels of several proteins involved in the epithelial‐to‐mesenchymal transition negatively correlated with miR‐590‐5p levels in lung adenocarcinoma cells and tumors of NSCLC patients. Further, dual‐luciferase reporter assays identified STAT3 as a direct target of miR‐590‐5p, which negatively regulated STAT3 activation and its downstream signaling molecules (eg, Cyclin D1, c‐Myc, Vimentin, and β‐catenin) involved in tumorigenesis. Taken together, our study suggests that miR‐590‐5p functions as a tumor suppressor in NSCLC through regulating the STAT3 pathway, and may serve as a useful biomarker for the diagnosis/prognosis of NSCLC, and as a potential therapeutic target for the treatment of NSCLC.

show abstract

“…The conventional treatment for lung cancer is whole-body chemotherapy with cisplatin, but the efficacy of such regimens is limited [ 5 ]. Although several biomarkers have been reported with lung cancer prognosis, including ELF3 [ 6 ], miRNA-135 [ 7 ], miRNA-34 [ 8 ], the survival status of lung cancer patients are still not satisfactory. Thus, further studies focusing on the mechanisms of initiation and progression, and the identification of prognostic molecular markers are of crucial significance.…”

Section: Introductionmentioning

confidence: 99%

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related death worldwide. The relationships of alcohol dehydrogenase (ADH) enzymes, encoded by the genes ADH1 (1A), ADH1B (ADH2), ADH1C (ADH3), ADH4, ADH5, ADH6, and ADH7, with NSCLC have not been studied. The aim of this study was to explore the associations between NSCLC prognosis and the expression patterns of ADH family members.Material/MethodsThe online resource Metabolic gEne RApid Visualizer was used to assess the expression patterns of ADH family members in normal and primary lung tumor tissues. The GeneMANIA plugin of Cytoscape software and STRING website were used to evaluate the relationships of the 7 ADH family members at the gene and protein levels. Gene ontology enrichment analysis and KEGG pathway analysis were performed using DAVID. The online website Kaplan-Meier Plotter was used to construct survival curves between NSCLC and ADH isoforms.ResultsThe prognosis of patients with high expression levels of the ADH1B, ADH1C, ADH4, and ADH5 genes was better than those with low expression in adenocarcinoma and all (containing adenocarcinoma and squamous cell cancer) histological types (all P<0.05). Low expression of ADH7 was associated with a better prognosis in patients with both the adenocarcinoma and squamous cell cancer histological types (P=9e-05). Moreover, expression of ADH family members was associated with smoking status, clinical stage, and chemotherapy status.ConclusionsADH1B, ADH1C, ADH4, ADH5, and ADH7 appear to be useful biomarkers for the prognosis of NSCLC patients.

show abstract

Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer

Cited by 48 publications

References 40 publications

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Identification of a long non‑coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About